04:02 AM EDT, 06/02/2025 (MT Newswires) -- Protagonist Therapeutics ( PTGX ) and Takeda (TAK) said Sunday their investigational drug rusfertide as a potential treatment for patients with polycythemia vera met primary and key secondary endpoints in a randomized, placebo-controlled phase 3 study. The companies, which are co-developing the drug, said 76.9% of patients in the 156-week, 293-patient study receiving...

04:17 AM EDT, 06/02/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that the phase III trial of its immunotherapy, Imfinzi, when used before and after surgery with chemotherapy, showed significant improvement in event-free survival in patients with gastric and gastroesophageal junction cancers. The company said the study showed patients treated with its neoadjuvant Imfinzi in combination with chemotherapy...

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

04:08 AM EDT, 06/02/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer. The company said its combination therapy reduced the risk of disease progression or death by 56%...